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Abstract
The review aimed at assessing the osteopromotive potential as well as soft tissue and temporomandibular joint
(TMJ) cartilage healing properties of simvastatin by summarizing its efficacy on the current dental treatment of
periodontal bone and soft tissue defects, and temporomandibular joint (TMJ) arthritis from the available animals
and human studies. An electronic search was performed on MEDLINE, Scopus, and Cochrane Central Register of
Controlled Trials (CENTRAL) using a combination of keywords. A hand search was undertaken on seven oral surgery
journals. No limitation of publication year in the English language was placed. Controlled randomized animal and
human clinical trials, as well as prospective comparative studies, were included. Data on the comparison of topical/
systemic simvastatin on bone healing in intrabony and furcation defects, extraction sockets, distraction
osteogenesis, as well as soft tissue healing in mucogingival grafting procedures and cartilage protection in TMJ
arthritis were extracted from all the eligible studies. Studies with a minimum of ten participants and follow up at
least 6 months were included. Ten animal studies and six clinical studies were included in this study. All the animal
studies included a minimum of eight sites per group assessed clinically, histologically, and radiographically. All
human studies included clinical and radiological evaluation. The results of the review show that simvastatin
administration displays positive treatment outcomes in the full range of therapies investigated in the oral regions
such as periodontal infection control, periodontal and alveolar bone regeneration, soft tissue grafting, TMJ
inflammation reduction, and cartilage repair. Its mechanism includes stimulating bone formation, promoting soft
tissue healing, increasing articular and condylar cartilage thickness, as well as reducing inflammation at surgical sites
in TMJ disorders. Simvastatin administration is beneficial to the healing of oral bone and cartilage. More studies are
desired to determine its potential in soft tissue healing.
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Background
Unlike any other type of tissue, bone and cartilage have
a complex morphology and exhibit very limited inherent
self-repair potentials. Many studies have suggested that a
non-union bone gap greater than 25 nm or even only
500 μm always remains after the primary,
non-interventional healing depending on the location,
vascularization, and the mechanics [1]. Following tooth
loss or extraction, without the mechanical stimulus from
teeth, alveolar bone naturally degrades to a significant
extent thus complicating prosthetic rehabilitation [2, 3].
When sufficient quantity and quality of the alveolar
bone is absent, the interventions of dental implants
could be complicated at the site for placement of im-
plants because of impaired osseointegration within atro-
phic alveolar bone ridge.
Approaches to regenerate bone include specific graft-
ing surgical techniques with autogenous bone, substi-
tutes, barrier membranes, growth factors, stem cell
therapy, and lately the osteopromotive pharmacological
* Correspondence: jchang@dental.ufl.edu
1Department of Periodontology, University of Florida College of Dentistry,
Gainesville, FL, USA
Full list of author information is available at the end of the article
International Journal of
Implant Dentistry
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Gupta et al. International Journal of Implant Dentistry            (2019) 5:17 
https://doi.org/10.1186/s40729-019-0168-4
compounds. The pharmacological approaches have
gained popularity owing to their convenience and the
advantageous cost-effectiveness when applied with other
grafting techniques. Among all the pharmacological
compounds, simvastatin has been well investigated since
the 90s for its osteopromotive properties. Simvastatin
belongs to the family of statins which are structural ana-
logs of HMG-CoA (3-hydroxy-3-methylglutaryl-coen-
zyme A). Stains could reversibly inhibit HMG-CoA
reductase through side chains that bind to the enzyme’s
active site and block the substrate–product transition
state of the catalyst. They are originally developed to
treat hypercholesterolemia. Commercially available -sta-
tin medicines include pravastatin, simvastatin, fluvasta-
tin, atorvastatin, cerivastatin, pitavastatin, and
rosuvastatin. Of all the statins, simvastatin is one of the
most commonly prescribed drugs [4]. The
osteoblast-stimulating effects of simvastatin were
highlighted by the breakthrough work of Mundy et al. in
1999. They reported that simvastatin could stimulate
bone regeneration and promote bone formation in the
mouse calvaria defect model [5]. The mechanism
simvastatin-mediated bone regeneration could be attrib-
uted to its osteoblast promoting, anti-inflammatory,
osteoclast inhibiting, and neovascularization properties
[6, 7]. The pleiotropic effects of simvastatin in bone me-
tabolism are associated with its induction of BMP-2 and
VEGF gene expression to stimulate the differentiation of
osteoblastic cells [8]. Meanwhile, simvastatin was found
to inhibit bone resorption by reducing expression of
TRAP and cathepsin K, preventing the fusion of osteo-
clast precursors, and decreasing the number of active os-
teoclasts [9]. Due to those new findings, the dental
clinicians investigate how to reposition this drug to treat
alveolar bone, oral soft tissue, and TMJ cartilage defects.
We summarized the approaches and findings of these
works in this paper and found that simvastatin adminis-
tration displays positive treatment outcomes in the full
range of therapies investigated in the oral regions such
as periodontal infection control, periodontal and alveolar
bone regeneration, soft tissue grafting, TMJ inflamma-
tion reduction, and cartilage repair.
A vast literature composed of in vitro experiments, in
vivo animal studies, and clinical studies investigated the
potential of simvastatin in bone, soft tissue, and cartilage
regeneration or protection in the scope of dentistry, with
varied results. The purpose of this systematic review was
to focus on the effects of simvastatin on healing en-
hancement in the oral cavity. We aimed to address the
following research questions:
1. Does the result vary with the dosage and what is
the ideal dose to be used clinically without adverse
effects?
2. Is there any difference in outcome with the route of
administration—local/ systemic?
3. What is the role of simvastatin in soft tissue
healing?
4. What is the reliability of simvastatin in promoting
bone formation with or without the adjunct of bone
grafts?
Materials and methods
Search strategy
This systematic review was reported following the Pre-
ferred Reporting Items for Systematic Review and
Meta-Analyses statement (PRISMA) [10]. An electronic
search was performed on the following databases: MED-
LINE, Scopus, and Cochrane Central Register of Con-
trolled Trials (CENTRAL). The last search was
performed on December 31, 2017. The search terms
used were “simvastatin,” “statin,” “bone healing,” “bone
density,” “osseointegration,” “dental implants,” “bone
graft,” “grafting,” “periodontal surgery,” “oral surgery,”
“extraction socket,” “tooth extraction.” These terms were
combined using Boolean operators OR and AND. Fur-
thermore, a hand search of issues from 2000 up to the
last issue available on December 15, 2017, including the
“Early view” (or equivalent) section was undertaken in
the following journals: British Journal of Oral and Max-
illofacial Surgery, International Journal of Oral and Max-
illofacial Surgery, Journal of Oral and Maxillofacial
Surgery, Journal of Periodontology, Journal of Clinical
Periodontology, Journal of Periodontal Research, Oral
Surgery, Oral Medicine, Oral Pathology, Oral Radiology
and Endodontology. The reference list of the retrieved
reviews and the included studies was also searched for
possible additional eligible studies not identified by the
electronic search.
Inclusion criteria
1. The studies report the results of dental procedures
(such as oral surgery, tooth extractions, periodontal
treatment, orthodontic treatment, TMJ arthritis therapy,
etc.) performed in human and animals, in which simva-
statin was topically or systemically used as an adjunct to
the standard surgical procedure.
2. The studies provide details on the method of
randomization, type and dosage of simvastatin used, the
duration of observation, and the report of any adverse
effects.
3. The studies compared a test group in which statins
were used, versus a control group without using the sta-
tins. The use of statins had to be the only difference be-
tween the test and control group.
The search was limited to oral surgical procedures in
animal and human studies published in the English lan-
guage only. Restrictions were not placed regarding the
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publication year. Only prospective studies were included.
No limitation on sample size was placed.
Exclusion criteria
Publications that did not meet the above inclusion cri-
teria and those that were not dealing with original clin-
ical cases (e.g., reviews, technical reports) were excluded.
In case of multiple publications relative to subsequent
phases of the same study or to enlargements of the ori-
ginal sample size, only the most recent data (those with
the longer follow-up and the larger sample size) were
considered.
Selection of the studies
Two reviewers (JC and SG) independently screened the
titles and the abstracts of the articles initially retrieved
through the electronic search. The concordance between
reviewers was assessed using Cohen’s Kappa coefficient.
In the case of disagreement, a third reviewer (MDF) was
consulted. The full texts of all studies of possible rele-
vance were independently assessed by the same two re-
viewers to check if they met all inclusion criteria. For
articles excluded at this stage, the reason for exclusion
was recorded.
Data extraction
Data were extracted by two reviewers independently
(MDF and SG). Cases of disagreement were subject to
joint evaluation until an agreement was reached.
The studies were initially categorized on the type of
animals used for the research as well as in the kind of
procedure performed. The primary variables extracted
further from each included study include study design,
sample size, type, dosage and administration route of
simvastatin, type of oral procedure, associated use of
grafting (yes/no), type of graft material, control treat-
ment, jaw (maxilla or mandible), follow-up duration, any
outcome variable used to evaluate treatment success,
outcomes used to assess radiographic, histological, and
histomorphometric bone healing.
The following methodological parameters were also
recorded such as the randomization method in random-
ized studies, the precise definition of outcomes assess-
ment, and the length of the follow-up period for all
studies.
Assessment of the quality of the trial
The methodological quality of the selected studies was
evaluated independently and in duplicate by two re-
viewers (MDF and SG) according to the above methodo-
logical parameters. In the case of disagreement, a third
reviewer (JC) was consulted. The risk of bias is assessed
based on criteria such as randomization, allocation con-
cealment, blinding of the examiner, completeness of
follow-up, and the similarity of groups at the start of the
study using modified Cochrane Collaboration’s tool for
assessment of bias. When all criteria were met, and no
more than one criterion was judged unclear, the risk of
bias was estimated as low; if two or more criteria were
judged unclear and other criteria were met, moderate
risk of bias was assigned; when one or more criteria
were not met, high risk was assigned. Besides, the as-
sessment parameters like completion and duration of
the study, dropouts, and statistical analysis methods ap-
propriateness were determined to declare the study as
adequate or inadequate. The authors of the included
studies were contacted for providing clarifications or
missing information as needed.
Outcome variables
The primary outcome variables included changes in hard
tissue parameters, such as bone/alveolar ridge width and
height, probing depth (PD), clinical attachment level
(CAL), radiographic defect fill, and bone mineral density.
The secondary outcome variables included the assess-
ment of levels of soft tissue inflammatory parameters at
the surgical sites.
Statistical analysis
If two or more comparative studies presented results re-
garding a similar outcome variable, they were aggregated
in a meta-analysis. The weighted mean difference be-
tween statin-treated and control group was estimated
using a random effect model with the software RevMan
(Version 5.3, The Nordic Cochrane Centre, The
Cochrane Collaboration, Copenhagen, 2014). Forest
plots were produced to graphically represent the differ-
ence in outcomes of statin-treated groups and placebo
groups for all included studies using defect site as the
analysis unit.
Results
The electronic search yielded 126 articles from the
period 2017–2005. Hand searching found an additional
19 articles. After a first screening of the titles and ab-
stracts, 38 articles reporting results of comparative stud-
ies that underwent oral surgery procedures in
combination with the use of statins were selected. After
evaluation of the full-text of these articles, only 16 ad-
equate studies including 10 animal studies and 6 human
studies with low risk of bias were considered for review
analysis. The meta-analysis was performed with human
studies. Animal studies were not considered for quanti-
tative analysis due to the difference in methodologies,
protocols, defect types, animal models, and outcome
variables. The flowchart summarizing the screening
process is presented in Fig. 1.
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Characteristics of the included studies
The characteristics of the included studies are described
in Tables 1, 2, and 3. The experimental models used in
these studies include rats, rabbits, and beagle dogs.
There were a total of ten animal studies. Among them,
two studies assessed the effect of systemically adminis-
tered simvastatin in ovariectomized rats. Vaziri et al. in
2007 determined the most effective dosage of simva-
statin (1 × 10−6, 1 × 10−7, and 3 × 10−7 M) for bone for-
mation in ligature-induced periodontitis rat model,
whereas Anbinder et al. in 2007 compared the effects of
systemic administration of 25 mg/kg of simvastatin with
the application of alendronate in both ovariectomized
and sham-operated rats for a period of 35 days [11, 12].
Both the studies demonstrated no superior results with
simvastatin as compared to controls.
Wu et al. 2008 and Sherif et al. 2016 assessed the ex-
traction and site preservation effect of 1 mg/ml of sim-
vastatin in PLGA gel and 2.5% simvastatin in 1 ml
chitosan gel respectively [13, 14]. Both studies concluded
that simvastatin is potential to preserve bone height and
bone mineral density (BMD). Increase in bone density
was reported at the periods between 1 and 4 weeks,
while the increase in bone height was only evident at
8 weeks [13]. Killeen et al. in 2012 conducted a study
comparing the effects of 0.5 mg of simvastatin with
0.5 mg simvastatin in alendronate-cyclodextrin conju-
gate on fenestration defects created on molar roots in a
rat model [15]. The study highlighted the osteopromo-
tive impact of local simvastatin when used in conjunc-
tion with systemically administered alendronate.
Rutledge et al. in 2011 compared simvastatin (10 mg)
with porous hydroxyapatite collagen sponges applied lo-
cally as well as injected in dehiscence defects in dogs.
The study demonstrated the ability of simvastatin to in-
duce bone growth at sites of thin bone and edentulous
sites [16]. Another study by Ozec et al. in 2007 com-
pared simvastatin (2.5 mg/ml) with gelatin sponges for
bone density in critical-sized defects in rats [17]. Healing
in closed defects like distraction osteogenesis was deter-
mined by Kilic et al. in 2008 in rabbits. The experimen-
tal group included simvastatin administered locally in
the dose of 2.5 mg/0.2 g of gelatin and 10 mg adminis-
tered systemically [18].
The human studies included in this analysis showed
greater homogeneity in the methodology than the ani-
mal studies [19–24]. Therefore, we performed a
meta-analysis on these six selected human clinical stud-
ies. Of all these six human studies, only one study inves-
tigated soft tissue healing potential of simvastatin. All
these clinical trials aimed to determine if simvastatin
intervention could benefit surgical approaches and
improve clinical and radiological parameters. The dos-
age of simvastatin used in all studies was 1.2 mg ex-
cept in the study by Gouda et al. in 2017 [23]. In this
study, the researchers conducted a split-mouth study
comparing 0.1 mg of simvastatin/14 mg of beta-TCP
to beta-TCP in maxillary sinus lifts. Although this
study included the least number of patients among all
the selected studies in this review, it exhibited the
strength in extending the follow-up to 9 months after
the surgeries.
Fig. 1 PRISMA flowchart of literature search and screening process
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Table 1 Summary of the studies on animal models
Author,
study type
Procedure and animal
type
Group and study type Key results
Sherif et al.
2016
RCT
20 rats, bilateral
extractions
Test group: 2.5% SIM gel
Control: no treatment
Rats sacrificed at 1st, 2nd, 3rd, and 4th week
Buccolingual ridge width measured with bone calipers
Single topical application of 2.5% simvastatin gel
improves the quality of the new bone of the healing
extraction socket and decreases bone resorption
Wu et al.
2008
RCT
60 rats, extraction Test group (30): SIM 1 mg/1 ml PLGA scaffold
Control: PLGA
Rats sacrificed at 1, 2, 4, 8, and 12 weeks.
Histology and BMD examination
Higher bone formation rate and quality were found
during the extraction socket healing in the
experimental group than in the control group at all
time points except for 1 week
Vaziri et al.
2007
RCT
49 rats, bilateral
ovariectomy
7 groups with ligature placed in all except 1 (sham)
Group 1 (N = 7), ovariectomy (OVX) plus simvastatin
(10–6 M); group 2 (N = 7), OVX plus simvastatin (3·10–
7 M); group 3 (N = 7), OVX plus simvastatin (10–7 M);
group 4 (N = 7), OVX plus normal saline; group 5 (N =
7), OVX group; group 6 (N = 7), ligature without OVX;
group 7 (N = 7), sham surgery without OVX and
ligature.
Sacrificed after 4 weeks.
Radiologic and histologic analysis. Bone loss,
attachment loss
Simvastatin inhibits periodontal attachment loss with
the least in 10–6 M group. 3·10–7 M had the least
effect on the inhibition.
Local application of simvastatin shows protective
features against the impact of periodontitis on
attachment apparatus and alveolar bone
Killeen et
al. 2012
RCT
Split-
mouth
study
65 rats, fenestration
defects
Test group: 0.5 mg simvastatin in ethanol (SIM-EtOH);
2) 0.5 mg simvastatin in alendronate–cyclodextrin
conjugate (SIM-ALN-CD); control group: 3) EtOH alone;
4) ALN-CD alone; or 5) no injections.
Sacrificed at 21 days, 48 days.
Histometric analysis
Twofold to threefold more new bone width (0.004)
was seen in the fenestration defect treatment with the
use of systemic ALN after SIM-EtOH injections as com-
pared to local SIM/ALN-CD preparations or short-term
SIM-EtOH injections
Kiliç E
et al. 2008
RCT
18 rabbits, unilateral
distraction
osteogenesis
Experimental group I: 2.5 mg/ml of SIM/0.2 g of
gelatin sponge applied locally
Experimental group II: 10 mg SIM systemically
Control: no treatment
Sacrificed at 14 days
Peripheral quantitative computed tomography, and
with histomorphometry
No SSD in the amount of regenerate bone during
distraction osteogenesis between the systemic
simvastatin group and control group or between the
local simvastatin group and control group
Rutledge et
al. 2011
Split-
mouth
study
4 beagle dogs,
dehiscence defects
bilaterally
Local placement of porous HA-collagen grafts with re-
sorbable membranes with or without 10 mg SIM
followed by local injections.
Sacrificed after 2 months
Histomorphometry
Locally injected SIM can induce modest amounts of
new bone formation within the dehiscence defects in
closed injection sites over a periosteal surface
Ozec et al.
2007
RCT
23 rats, critical-sized
defects in the
mandibles
Experimental group: 2.5 mg/Ml SIM mixed with 0.02 g
of gelatin sponge.
Passive control
Active control: gelatin sponge mixed with water
Sacrificed at day 14
Radiology and histology assessment
New bone formation and density of new bone in
mandibular defects are more significant in the
experimental group than control groups
Anbinder
et al. 2007
RCT/Split
mouth
54 rats, two groups:
ovariectomized (OVX)
or sham operated
Experimental group: simvastatin (SIN–25 mg/kg),
Active control: sodium alendronate (ALN–2 mg/kg) or
Passive control: water (control) orally.
Sacrificed after 35 days
Radiographic bone density measured
No SSD in alveolar bone formation between ALN and
SIM group
George MD
et al. 2013
RCT
32 rats, randomized
5 groups. TMJ
inflammation induced
I: Controls
II: ETH III: 0.1 mg SIM, 3) IV: 0.5 mg SIM, V: 0.15 mg TH.
Time: 28 days
H&E
SIM & TH reduced the TMJ articular layer thickness,
0.5 mg decreased inflammation
Holwegner
et al. 2015
RCT
44 mature rats
CFA induced
inflammation in right
TMJ
6 groups
I: CFA + 0.5 SIM
II: CFA + EtOH
III: CFA + 0.15 TH
IV: CFA + SIM + H V: CFA
VI: Control (left)
Time: 4 weeks
CT, BV, BMD
CFA combination groups: TMJ ramus height > than
CFA alone
BV:CFA + 0.5 SIM > CFA + SIM + TH
Condylar width, bone density: least in steroid grp as
compared to SIM
SIM simvastatin, HA hydroxyapatite, TH triamcinolone hexacetonide, CFA complete Freund’s adjuvant, EtOH ethanol
Gupta et al. International Journal of Implant Dentistry            (2019) 5:17 Page 5 of 11
The parameters of all selected studies included the
changes in probing depth and clinical attachment levels.
Some studies evaluated bone density (gray levels) and
bone fill. One study investigated soft tissue parameters.
Among them, Kinra et al. in 2010 compared simvastatin
(10−8 M/mg of DFDBA) to DFDBA in bilateral
two-walled and three-walled defects [19]. Ranjan et al. in
2017 assessed bone formation in intrabony defects by
comparing open flap debridement (OFD) and a placebo
to OFD with 1.25% simvastatin in the defects [20]. Pra-
deep et al. in 2012 performed a 6-month prospective
study on 72 patients and compared scaling root planning
(SRP) to SRP in combination with 1.2 mg simvastatin in
class II furcation defects. This study included the highest
patient number and the longest follow-up period [21].
Chauhan et al. in 2015 determined the site healing pat-
tern in extraction sockets with 10 mg simvastatin. It also
assessed the effects of simvastatin on patients’ comfort,
post-op swelling, and pain [22]. Impact of statins on
cartilage healing has also been studied in
intra-articular-induced arthritis models in rats [37, 38].
The studies suggested that 0.5 mg of simvastatin has the
potential to reduce sub-synovial inflammation and indu-
cing new bone formation in steroid-induced bone re-
sorption sites.
Results of analysis for bone height in animal studies and
meta-analysis for CAL in human studies
Two animal studies assessed the effect of simvastatin on
the bone height in extraction sockets [11, 13], and one
evaluated the changes of bone height in the
ligature-induced periodontitis with simvastatin treat-
ment [14]. Even though all these studies suggested that
simvastatin may have a beneficial effect, due to consist-
ent differences in the protocols, outcome variables, and
evaluation methods among these studies, it was not feas-
ible to estimate an overall effect with meta-analysis.
Table 2 Summary of human studies
Author Procedure type Group and study type Key results
Gouda et
al. 2017
Bilateral
RCT
6 patients
8 sinus lifts in sites with < 8 mm
available bone.
CBCT at 1 week and 9 months to
determine the change in bone
height and %age of bone loss.
Histomorphometry to determine new
bone formation rate
Experimental group: 7.21 mg simvastatin/1 g beta-
TCP
Control: beta-TCP
SSD in new bone formation of maxillary
sinus bone grafting. More in the SIM
group.
No SSD in the amount of bone loss
between both groups
Ranjan et
al. 2017
RCT
20 patients, 40 bilateral periodontal
intrabony defects.
Open flap debridement.
Clinical and radiographic outcomes
Experimental group: OFD + 1.2 SIM compared to
Control: OFD + placebo.
GI, PI, PD, CAL at 3, 6, 9 months.
Bone fill assessment
SSD decrease in PD. GI and increase in
CAL in the experimental group.
No SSD in PI.
SSD increase in the amount and
percentage of bone fill in the
experimental group
Kinra et
al. 2010
Bilateral
RCT
15 patients
Bilateral 2-walled or 3-walled peri-
odontal intrabony defects.
Regenerative periodontal therapy
with bone grafts.
Clinical and radiographic outcomes
Experimental group: DFDBA and SIM (10–8 M)
Control group: DFDBA
PI, PD, intrabony pocket depth at 10, 24 weeks
SSD in an increase in bone fill, CAL gain,
reduction in PD in the experimental group
Chauhan
et al.,
2015
Bilateral
RCT
30 patients
Bilateral impacted mandibular third
molar extraction sockets.
Extraction and site preservation.
Clinical and radiographic outcomes
Experimental group: Gelfoam with 10 mg simvastatin
Control: Gelfoam
Pain, swelling, bone density with software at
3 months
No SSD in facial swelling and pain
between both groups.
SSD increase in bone density (calculated
by gray level histogram) in the
experimental group
Pradeep
et al.
2012
Bilateral
RCT
72 patients
Mandibular molar buccal Class II
furcation defects.
Non-surgical periodontal therapy.
Radiographic assessment of (PD),
(RVAL) vertical and horizontal (RHAL)
attachment levels
Group I: SRP plus placebo
Group II: SRP plus 1.2-mg SIM
Recall at Baseline, 3 and 6 months
SSD in the experimental group < control
SSD in PD in the experimental group at all
periods.
SSD increase in bone fill, RVAL, RHAL in
the experimental group
Madi M,
Kassem A
2018
RCT
N = 40
Free gingival graft procedure.
Visual analog scale for pain and
discomfort scoring.
Wound healing score
4 groups: group I: Simvastatin suspension (S), group II:
simvastatin/chitosan gel (SC), group III: chitosan gel
(C), group IV: petroleum gel (P).
Recall at 1, 3, 5, 7, 14 days
SSD in VAS and wound healing score at 3,
7, 15 days in the group II, simvastatin/
chitosan gel (SC) application
DFDBA demineralized freeze-dried bone allograft, TCP tricalcium phosphate, OFD open flap debridement, SSD statistical significant difference, GI gingival index, PI
plaque index, PD probing depth, CAL clinical attachment level, SRP scaling and root planning, SIM simvastatin, VAS visual analog scale
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Three human studies assessed the changes in CAL
(Fig. 2a) and PD (Fig. 2b) in periodontal defects [19–21].
There was evidence of a significant benefit of simvastatin
for both CAL gain (mean difference 1.50 mm, p < 0.001,
95% CI = 1.19, 1.82 mm) and PD reduction (mean differ-
ence 2.01 mm, p < 0.001, 95% CI = 1.41, 2.61 mm). All
the studies favored the statin-treated group. The study
by Gouda et al. [23] also showed a significant positive ef-
fect of statin on bone height improvement in the maxil-
lary sinus augmentation. But we did not perform a
meta-analysis on these topics because it is the only study
on such procedure.
Results of analysis for bone width in animal studies and
meta-analysis for defect bone fill in human studies
Four animal studies investigated the changes in bone fill
after dental treatment with the use of simvastatin [14–
16, 18]. Among these studies, one study was conducted
on dehiscence [16], one on fenestration defects [15], one
study was on tooth extraction defects [14], and one on
distraction osteogenesis [18]. Except for the study on
fenestration, all the other studies showed a positive ef-
fect of simvastatin, although no statistical significance
was reached in two studies [16, 18]. Due to heterogen-
eity in the protocols and outcome measures, no
meta-analysis could be performed to summarize the re-
sults of these studies.
Three human studies assessed the changes in the
width of alveolar ridge evaluating bone fill radiographic-
ally [19–21]; we found the significant improvement of
alveolar ridge width in the simvastatin group than its
control group (mean difference = 1.40 mm, p < 0.001,
CI = 0.99, 1.81 mm) (Fig. 3).
Results for analysis for bone mineral density in animal
studies
Five animal studies investigated whether simvastatin ap-
plication alters bone mineral density (BMD) [11–13, 17,
18]. Vaziri et al. in 2007 measured bone matrix resorp-
tion in ovariectomized rats using a dental X-ray unit,
Table 3 Characteristics of the included studies
Included
studies
Clear inclusion and
exclusion criteria
Randomization
method
Assessment parameters (two or more)/
validated measurements
Duration of
study
With/without carrier
and route
Risk of
bias
Vaziri et al.
2007
✓ No 2 4 weeks No carrier/injection Low
Killeen et al.
2012
✓ No 1 48 days Systemic/local
injection
Low
Kilic et al. 2008 ✓ No 2 14 days Systemic/local Low
Rutledge et al.
2011
✓ No 1 60 days Local injections Low
Ozec et al.
2007
✓ No 2 14 days Systemic Low
Sherif et al.
2016
✓ No 1 4 weeks Topical Low
Wu Z et al.
2008
✓ No 2 12 weeks Local Low
Anbinder et al.
2007
✓ Yes 1 35 days Oral Low
George MD et
al. 2013
✓ No 1 30 days Injections/carrier Low
Holwegner et
al. 2015
✓ No 2 28 days Injections/carrier Low
Gouda et al.
2017
✓ No 2 9 months Local Low
Ranjan et al.
2017
✓ No 2 9 months Local Low
Kinra et al.
2010
✓ No 2 24 weeks Local Low
Chauhan et al.
2015
✓ No 2 3 months Local Low
Pradeep et al.
2012
✓ No 2 6 months Local Low
Madi and
Kassem. 2018
✓ No 2 14 days Topical Low
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and giving densitometric measurement values in mm
[11]. Anbinder et al. in 2007 measured BMD in ovariec-
tomized rats with a digital dental X-ray unit, giving op-
tical density values in gray levels [12]. Wu et al. in 2008
measured BMD with dual-energy X-ray absorptiometry
(DXA) and provided the results in the unit of mg/cm2
[13]. Kilic et al. in 2008 measured BMD changes in rab-
bits by peripheral quantitative computed tomography
(pQCT) and represented the results in a Hounsfield
scale [18]. Ozec et al. in 2007 were excluded from the
final analysis because this study did not provide suffi-
cient data [17]. These four studies all showed the mild
Fig. 2 Meta-analysis using a random effect model for assessing bone height changes in various types of defects in human studies. a Clinical
attachment level (CAL) changes at 6 months. b Probing depth (PD) reduction. Significant positive effect of simvastatin was found in both cases.
Heterogeneity was found for PD (I2 = 87%, p = 0.0004), but not for CAL (I2 = 43%, p = 0.17). Mean differences and 95% confidence intervals are
expressed in mm
Fig. 3 Meta-analysis using a random effect model for assessing bone fill in various types of defects in human studies. Overall analysis showed a
significant positive effect of simvastatin in enhancing bone defect fill (p < 0.0001). Slight heterogeneity among studies was found (I2 = 70%, p =
0.03). Mean differences and 95% confidence intervals are expressed in mm
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positive effect of simvastatin on BMD, but without the
statistical difference. Due to the methodological differ-
ences, it was not feasible for us to aggregate the results
of BMD changes using a meta-analysis.
Discussion
Simvastatin was repositioned to anti-inflammatory and
osteopromotive purpose recently. Researchers found that
simvastatin could accelerate bone regeneration and soft
tissue healing by increasing osteoblastic differentiation
and stimulating neovascularization via its influence on
bone morphogenetic proteins and endothelial growth
factor [24, 25]. Statins may also show the
anti-inflammatory effect by inhibiting the tissue degrad-
ing enzymes like matrix metalloproteinase (MMPs) in
rheumatoid arthritis [26]. In the present review, we want
to summarize the application of simvastatin in the scope
of dental treatments including periodontal regeneration,
bone grafting in tooth extraction sockets, distraction
osteogenesis, soft tissue healing after mucogingival graft-
ing, and TMJ arthritis therapy. The results of the present
systematic review showed that simvastatin has a positive
effect on bone regeneration, soft tissues healing, and
TMJ articular cartilage healing. Such clinical findings are
consistent with the statins’ biological function [27]. For
example, the significantly higher alveolar bone level/
amount and attachment level in periodontitis patients
with simvastatin intervention could be contributed to its
synergistic effect of reduced anti-inflammatory response,
less soft and hard tissue degradation, and enhanced
wound healing potential.
The dosage of simvastatin for dental osteogenic pur-
pose varied from as low as 1.2 mg applied locally to
10 mg/kg/day administered systemically. Interestingly,
the anti-inflammatory and osteopromotive properties of
simvastatin intervention are related to its dose. Wang et
al. reported that 5–10 mg/kg/day applied locally in the
fracture region supported bone healing [28]. High dose
of simvastatin (20 mg/kg/day) increases bone formation,
whereas low dose (1 mg/kg/day) decreases bone forma-
tion and induces bone resorption [29]. Two human trials
in this systemic study showed 0.1 mg simvastatin/14 mg
beta-TCP in tooth extraction sockets, and 10 mg simva-
statin/2 ml gel foam applied in maxillary sinus lifts in-
creased bone formation [22, 23]. Gutierrez et al. in 2006
determined that the topical application of statin was 50
times more efficient to promote bone formation than
the oral administration [30]. While Kilic et al. in 2008
reported no significant difference between the local and
systemic application of simvastatin in enhancing bone
density in a model of distraction osteogenesis [18]. Rut-
ledge et al. in 2011 reported a 240% increase in bone
density with the local application of simvastatin in man-
dibular defects [16]. However, Kilic et al. reported the
bone surface area was higher in the local application
group, although it did not reach statistical difference.
Overall, timing, dose, administration manner, and sched-
ule of simvastatin are all important factors to be consid-
ered how to perform simvastatin intervention in
dentistry. From the researches as mentioned earlier, 0.5–
1 mg of simvastatin falls within safe limits for intraoral
topical applications. The dose of simvastatin to treat the
systemic bone loss such as osteopenia or osteoporosis
was examined by several studies. Ho et al. in 2009
showed that simvastatin (20 mg/kg/day) enhances bone
formation by increasing osteoblast numbers and osteo-
genic protein expression in ovariectomized rats [31].
This was proved by the increased bone density, bone
height, and better bone defect healing by Vaziri et al.,
Anbinder et al., and Junqueira et al.’s study [11, 12, 32].
However, Anbinder et al. reported no statistical differ-
ence was found when systemically administered 25 mg/
kg/day simvastatin with alendronate (2 mg/kg/day) in
ovariectomized rats [12]. Therefore, based on all cur-
rently available studies, we cannot draw a clear conclu-
sion about the dose and intervention pathways for either
local or systemic administration of simvastatin for our
dental treatment. More studies are required to optimize
its clinical administration.
Simvastatin is a lipophilic drug. Hence, to increase its
absorption at the local sites and to delay the release of
drug thereby achieving a sustained release, simvastatin is
usually mixed with carriers like ethanol, chloroform, and
methanol [22], or mixed it with bone graft materials
such as DFDBA and beta-TCP [19, 23]. Nyan et al. in
2009 and other research explained the burst release
phenomenon of simvastatin from the graft particles on
the first day followed by slow release. This is advanta-
geous as the optimal dose of the drug stimulates local
cells to express BMP-2 without inducing the inflamma-
tory reaction [33–36]. Another reason to use carriers is
for space maintenance, for which thermosensitive mate-
rials are usually considered. These materials change their
form from liquid to semi-solid, which aids in retaining
the drug at a specific site for a longer duration of time.
Hence, one of the aims in the present systematic review
was directed at determining the outcomes after the ad-
ministration of simvastatin with and without a carrier.
Studies by Sherif et al., Holwegner et al., and George et
al. [14, 37, 38] reported no statistically significant differ-
ences in their results between the two groups. Rutledge
et al. and Ozec et al. [16, 17] have used gel foam and
collagen sponges as carriers with simvastatin to deter-
mine, if any advantage was obtained, with the use of re-
spective compounds. Rutledge et al. [16] in his study
reported that the use of ethanol prevents the backflow
of the drug compared to carriers like methylcellulose
due to their thermosensitive property. Also, in the same
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study, they compared the effects of simvastatin on bone
formation with or without the adjunctive use of bone
grafts. Though they observed a significant difference in
the bone formation between the two groups, the results
were not statistically significant. Sherif et al. [14] in his
paper further commented that there is no definite con-
sensus on the indications for the use of carriers and it is
determined by the type of surgical procedure.
In the present review, we also review the study investi-
gating simvastatin intervention on the healing of articu-
lar cartilage. Two recent studies determined the
outcome of simvastatin injections on experimental tem-
poromandibular arthritis in rats. In one of the studies, a
dose of simvastatin compared was 0.1 and 0.5 mg,
whereas in the other study, 0.5 mg of simvastatin was
compared with the 0.15 mg of triamcinolone hexaceto-
nide (steroids) injections [37, 38]. The period for assess-
ment was 28 days in both. Both the studies concluded
by agreeing on the anti-inflammatory property of simva-
statin. It was also suggested that simvastatin could pre-
serve normal condylar growth of cartilaginous tissue, if
not additive to the present extension. Also, 0.5 mg was
found to be better than 0.1 mg in reducing retrodiscal
inflammation which collaborates with the previous stud-
ies on the comparison of various doses of simvastatin.
The study had recorded that 0.1 mg was associated with
the least inflammatory reaction. However, there was in-
creased bone formation and anti-inflammatory effect
with 0.5 mg simvastatin [33, 39].
The soft tissue healing potential of statins has also
been established in a very recent study by Madi and Kas-
sem [40]. The study assessed palatal healing with simva-
statin and chitosan combination (10 mg/ml) after free
gingival graft procedure. A visual analog scale deter-
mined pain discomfort at various time intervals up to
14 days. Pain scores were comparatively reduced with
simvastatin at 7 days as compared to the control group
which consisted of simvastatin and chitosan alone. It
was concluded that the topical application of simvastatin
and chitosan gel could be used as a novel therapeutic
modality that improved healing and reduced pain in the
palatal donor site following the FGG procedure.
There are certain limitations noted in the current ana-
lysis such as (1) only 16 studies were included for the ana-
lysis based on a strict selection criterion, (2) studies had
small sample sizes, and (3) different study designs which
led to calibration error while documenting the results.
However, the present review draws its strength from the
strict selection bias and selection of the studies with con-
clusions drawn from the long duration of follow up.
Conclusion
The data from the available studies suggest that simva-
statin alone has a promising potential for alveolar bone
regeneration in the optimal dose of 0.5–10 mg depend-
ing on the route of administration. The use of simva-
statin with other bone grafts poses an additional
advantage. However, there are contradictory results in
literature; hence, more studies are needed for the same.
A definitive consensus could not be reached on the use
of carriers with simvastatin, and the usage of the carrier
is determined by the site and type of surgical procedure.
Despite positive outcomes for the healing of gingival
graft, more clinical studies are needed to support the use
of simvastatin for this application.
Acknowledgments
Not applicable.
Funding
This study is supported by the UFCD start-up grant to Dr. Jia Chang
#00127658.
Availability of data and materials
The datasets used and analyzed during the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
JC and SG performed the search, conducted the review, and drafted the
manuscript. MDF assisted in assessing the studies, carried out the editing of
the manuscript, and helped in the manuscript drafting. SG and MDF
designed the systematic review and performed data extraction
independently. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This review was executed by PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses), and no approval by an ethics com-
mittee was required.
Consent for publication
Not applicable.
Competing interests
Swati Gupta, Massimo Del Fabbro, and Jia Chang declare that they have no
competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Periodontology, University of Florida College of Dentistry,
Gainesville, FL, USA. 2Department of Biomedical, Surgical and Dental
Sciences, Università degli Studi di Milano, Milan, Italy. 3IRCCS Orthopedic
Institute Galeazzi, Milan, Italy.
Received: 8 September 2018 Accepted: 19 February 2019
References
1. Johner R. Dependence of bone healing on defect size. Helv Chir Acta. 1972;
39:409–11.
2. Hughes FJ, Ghuman M, Talal A. Periodontal regeneration: a challenge for
the tissue engineer? Proc Inst Mech Eng H. 2010;224:1345–58.
3. Hämmerle CH, Karring T. Guided bone regeneration at oral implant sites.
Periodontol 2000. 1998;17:151–75.
4. Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J
Pharm Pharmacol. 2006;58:3–18.
5. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of
bone formation in vitro and in rodents by statins. Science. 1999;286:1946–9.
Gupta et al. International Journal of Implant Dentistry            (2019) 5:17 Page 10 of 11
6. Yamashita M, Otsuka F, Mukai T, Yamanaka R, Otani H, Matsumoto Y,
Nakamura E, Takano M, Sada KE, Makino H. Simvastatin inhibits osteoclast
differentiation induced by bone morphogenetic protein-2 and RANKL
through regulating MAPK, AKT and Src signaling. Regul Pept. 2010;162(1-3):
99-108.
7. Sonobe M, Hattori K, Tomita N, Yoshikawa T, Aoki H, Takakura Y, et al.
Stimulatory effects of statins on bone marrow-derived mesenchymal stem
cells. Study of a new therapeutic agent for fracture. Biomed Mater Eng.
2005;15:261–7.
8. Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N.
Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J
Cell Biochem. 2004;92(3):458-71.
9. Grasser WA, Baumann AP, Petras SF, Harwood HJ Jr, Devalaraja R,
Renkiewicz R, et al. Regulation of osteoclast differentiation by statins. J
Musculoskelet Neuronal Interact. 2003;3:53–62.
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche Peter C, Ioannidis John
PA, et al. The PRISMA statement for reporting systematic reviews and meta-
analyses of studies that evaluate health care interventions: explanation and
elaboration. Ann Intern Med. 2009;151:W65–94.
11. Vaziri H, Naserhojjati-Roodsari R, Tahsili-Fahadan N, Khojasteh A, Mashhadi-
Abbas F, Eslami B, et al. Effect of simvastatin administration on periodontitis-
associated bone loss in ovariectomized rats. J Periodontol. 2007;78:1561–7.
12. Anbinder AL, Prado Fde A, Prado Mde A, Balducci I, Rocha RF. The influence
of ovariectomy, simvastatin and sodium alendronate on alveolar bone in
rats. Braz Oral Res. 2007;21:247–52.
13. Wu Z, Liu C, Zang G. The effect of simvastatin on remodelling of the
alveolar bone following tooth extraction. Int J Oral Maxillofac Surg. 2008;37:
170–7.
14. Sherif YM, Masry NE, Karam SS, Nasra MA. Evaluation of local administration
of simvastatin on height and width of the healing extraction socket in rat
mandible. Alex Dent J. 2016;41:283–6.
15. Killeen AC, et al. Impact of local and systemic alendronate on simvastatin-
induced new bone around periodontal defects. J Periodontol. 2012;83:
1463–71.
16. Rutledge J, Schieber MD, Chamberlain JM, Byarlay M, Killeen AC, Giannini PJ.
Simvastatin application to augment facial jaw bone in a dog model: pilot
study. J Periodontol. 2011;82:597–605.
17. Ozec I, Kilic E, Gumus C, Goze F. Effect of local simvastatin application on
mandibular defects. J Craniofac Surg. 2007;18:546–50.
18. Kilic E, Ozeç I, Yeler H, Korkmaz A, Ayas B, Gumuş C. Effects of simvastatin on
mandibular distraction osteogenesis. J Oral Maxillofac Surg. 2008;66:2233–8.
19. Kinra P, Gupta H, Mohammad KS, Ahmad S. Evaluation of the relative
efficacy of an allograft used alone and that in combination with simvastatin
in the treatment of human periodontal infrabony defects—a clinical and
radiological study. J Taibah Univ Med Sci. 5:75–88.
20. Ranjan R, Patil SR, H R V. Effect of in-situ application of simvastatin gel in
surgical management of osseous defects in chronic periodontitis—a
randomized clinical trial. J Oral Biol Craniofac Res. 2017; 7:113–118.
21. Pradeep AR, Priyanka N, Kalra N, Naik SB, Singh SP, Martande S. Clinical
efficacy of subgingivally delivered 1.2-mg simvastatin in the treatment of
individuals with class II furcation defects: a randomized controlled clinical
trial. J Periodontol. 2012;83:1472–9.
22. Chauhan AS, Maria A, Managutti A. Efficacy of simvastatin in bone
regeneration after surgical removal of mandibular third molars: a clinical
pilot study. J Maxillofac Oral Surg. 2015;14:578–85.
23. Gouda A, Helal E, Ali S, Bakry S, Yassin S. Maxillary sinus lift using
osteoinductive simvastatin combined with β-TCP versus β-TCP—a
comparative pilot study to evaluate simvastatin enhanced and accelerated
bone formation. Acta Odontol Scand. 2017;76:39–47.
24. Alam S, Ueki K, Nakagawa K, Marukawa K, Hashiba Y, Yamamoto E, et al.
Statin-induced bone morphogenetic protein (BMP) 2 expression during
bone regeneration: an immunohistochemical study. Oral Surg Oral Med
Oral Pathol Oral Radiol Endod. 2009;107:22–9.
25. Maeda T, Kawane T, Horiuchi N. Statins augment vascular endothelial
growth factor expression in osteoblastic cells via inhibition of protein
prenylation. Endocrinology. 2003;144:681–92.
26. Leung BP, Sattar N, Crilly A, Prach M, Carey M, Payne DW, et al. A novel anti-
inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;
170:1524–30.
27. Bertl K, Pietschmann P, Stavropoulos A. Chapter 12: Osteoimmunological
aspects of periodontal diseases. In: Pietschmann PP, ed. Principles of
Osteoimmunology: Molecular Mechanisms and Clinical Applications. Cham,
Switzerland: Springer; 2016. p. 289-321.
28. Wang SP, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and
the risk of hip fractures in elderly patients. J Am Med Assoc. 2000;283:3211–6.
29. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on
bone mineral density and bone histomorphometry in rodents. Arterioscler
Thromb Vasc Biol. 2001;21:1636–41.
30. Gutierrez GE, Lalka D, Garrett IR, Rossini G, Mundy GR. Transdermal
application of lovastatin to rats causes profound increases in bone
formation and plasma concentrations. Osteoporos Int. 2006;17:1033–42.
31. Ho ML, Chen YH, Liao HJ, Chen CH, Hung SH, Lee MJ, et al. Simvastatin
increases osteoblasts and osteogenic proteins in ovariectomized rats. Eur J
Clin Investig. 2009;39:296–303.
32. Junqueira JC, Mancini MN, Carvalho Y, Anbinder AL, Balducci I, Rocha RF.
Effects of simvastatin on bone regeneration in the mandibles of
ovariectomized rats and on blood cholesterol level. J Oral Sci. 2002;44:117–24.
33. Nyan M, Sato D, Kihara H, Machida T, Ohya K, Kasugai S. Effects of the
combination with alpha-tricalcium phosphate and simvastatin on bone
regeneration. Clin Oral Implants Res. 2009;20:280–7.
34. Rojbani H, Nyan M, Ohya K, Kasugai S. Evaluation of the osteoconductivity
of a-tricalcium phosphate, b-tricalcium phosphate, and hydroxyapatite
combined with or without simvastatin in rat calvarial defect. J Biomed
Mater Res A. 2011;98:488–98.
35. Zerbo IR, Zijderveld SA, de Boer A, et al. Histomorphometry of human sinus
floor augmentation using a porous beta-tricalcium phosphate: a prospective
study. Clin Oral Implants Res. 2004;15:724–32.
36. Zijderveld SA, Zerbo IR, van den Bergh JP, Schulten EA, ten Bruggenkate
CM. Maxillary sinus floor augmentation using a beta-tricalcium phosphate
(Cerasorb) alone compared to autogenous bone grafts. Int J Oral Maxillofac
Implants. 2005;20:432–40.
37. George MD, Owen CM, Reinhardt AL, Giannini PJ, Marx DB, Reinhardt RA.
Effect of simvastatin injections on temporomandibular joint inflammation in
growing rats. J Oral Maxillofac Surg. 2013;71:846–53.
38. Holwegner C, Reinhardt AL, Schmid MJ, Marx DB, Reinhardt RA. Impact of
local steroid or statin treatment of experimental temporomandibular joint
arthritis on bone growth in young rats. Am J Orthod Dentofac Orthop.
2015;147:80–8.
39. Stein D, Lee Y, Schmid MJ. Local simvastatin effects on mandibular bone
growth and inflammation. J Periodontol. 2005;76:1861–70.
40. Madi M, Kassem A. Topical simvastatin gel as a novel therapeutic modality
for palatal donor site wound healing following free gingival graft
procedure. Acta Odontol Scand. 2018;76:212–9.
Gupta et al. International Journal of Implant Dentistry            (2019) 5:17 Page 11 of 11
